Login
Companies $EDIT
$1.96 +$0.09 (4.81%) After hours
Editas Medicine, Inc. logo

Editas Medicine, Inc.

editasmedicine.com

What Do They Do?

Develops CRISPR gene-editing medicines for people with serious diseases and licenses gene-editing technology to pharmaceutical and biotechnology partners.

How Do They Make Money?

Partners pay upfront for licenses, reimburse research and development work, and may make additional payments when development, regulatory, or sales milestones are reached; royalties are tied to licensed-product sales.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical and biotechnology companies collaborate with Editas to develop gene-edited medicines or license gene-editing rights; relationships described include Bristol Myers Squibb/Juno Therapeutics, Immatics, and Vertex.

Do Revenues Turn Into Profits?

No. It lost $160.1M in FY2025.

Operating income, FY2025
−395% of revenue
▲ +36% (Loss) vs FY2024 (−$251.2M, −777%)
Net income, FY2025
−395% of revenue
▲ +32% (Loss) vs FY2024 (−$237.1M, −734%)
Free cash flow, FY2025
−409% of revenue
▲ +24% (Loss) vs FY2024 (−$219.1M, −678%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +37%
vs $7.5M in Q3 FY2025
Net income
▲ +7% (Loss)
vs −$25.1M in Q3 FY2025
  • Apr 1, 2026 Editas replaced Ernst & Young with PwC as its auditor The audit committee solicited proposals and conducted a formal review before appointing PwC.

Growing. Revenue grew 59% in 4 years, from $25.5M in FY2021 to $40.5M in FY2025, about 12% a year.

From ex vivo to in vivo The older report centered on an ex vivo HSC medicine for sickle cell disease and beta thalassemia, alongside next-generation in vivo work. The latest report says it stopped pursuing reni-cel commercialization and centers development on an in vivo treatment for hyperlipidemia.

Who Do They Compete With?

Competes with AccurEdit Therapeutics, CRISPR Therapeutics, Eli Lilly, EmendoBio, nChroma Bio, Scribe Therapeutics, Tune Therapeutics, Yoltech Therapeutics, Amgen, Arrowhead Therapeutics, LIB Therapeutics, Merck, NewAmsterdam Pharma, Novartis, Regeneron Pharmaceuticals, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Caribou Biosciences, and Sarepta Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support